Literature DB >> 8844985

Expression of truncated midkine in human colorectal cancers.

I Miyashiro1, T Kaname, T Nakayama, S Nakamori, T Yagyu, T Monden, N Kikkawa, I Nishisho, T Muramatsu, M Monden, T Akiyama.   

Abstract

Midkine (MK) is a growth differentiation factor originally found as the product of a retinoic acid-responsive gene. The expression of MK was examined in 35 surgically resected specimens of primary colorectal cancer using the reverse transcription-polymerase chain reaction (RT-PCR). All of the cancerous tissues expressed MK. In 5/25 cancerous tissues a truncated form of MK, which was recently found in various human tumor cell lines, was detected in addition to the full-size MK. In contrast, the truncated from of MK could not be detected in non-cancerous tissues, whereas the wild-type form was detected in 8/10 non-cancerous tissues. These results suggest that the expression of the truncated form of MK may be associated with tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8844985     DOI: 10.1016/0304-3835(96)04333-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

Review 1.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

2.  Over-expressed and truncated midkines promote proliferation of BGC823 cells in vitro and tumor growth in vivo.

Authors:  Qing-Ling Wang; Hui Wang; Shu-Li Zhao; Ya-Hong Huang; Ya-Yi Hou
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

3.  The advances of Midkine with peripheral invasion in pancreatic cancer.

Authors:  Jun Yao; Wen-Yao Li; She-Gan Gao
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

4.  Midkine's Role in Cardiac Pathology.

Authors:  Kathleen C Woulfe; Carmen C Sucharov
Journal:  J Cardiovasc Dev Dis       Date:  2017-08-24

5.  Serum Midkine is a clinical significant biomarker for colorectal cancer and associated with poor survival.

Authors:  Marius Kemper; Wiebke Hentschel; Julia-Kristin Graß; Bjoern-Ole Stüben; Leonie Konczalla; Tamina Rawnaq; Tarik Ghadban; Jakob R Izbicki; Matthias Reeh
Journal:  Cancer Med       Date:  2020-01-26       Impact factor: 4.452

6.  Tumor location determines midkine level and its association with the disease progression in colorectal cancer patients: a pilot study.

Authors:  Malgorzata Krzystek-Korpacka; Dorota Diakowska; Krzysztof Grabowski; Andrzej Gamian
Journal:  Int J Colorectal Dis       Date:  2012-05-06       Impact factor: 2.571

7.  Midkine as a prognostic biomarker in oral squamous cell carcinoma.

Authors:  K Ota; H Fujimori; M Ueda; S Shiniriki; M Kudo; H Jono; Y Fukuyoshi; Y Yamamoto; H Sugiuchi; H Iwase; M Shinohara; Y Ando
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

8.  Truncated midkine as a marker of diagnosis and detection of nodal metastases in gastrointestinal carcinomas.

Authors:  K Aridome; S Takao; T Kaname; K Kadomatsu; S Natsugoe; F Kijima; T Aikou; T Muramatsu
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

9.  Midkine: a novel prognostic biomarker for cancer.

Authors:  Hirofumi Jono; Yukio Ando
Journal:  Cancers (Basel)       Date:  2010-04-20       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.